Cardiology Headline News

CHICAGO — Hormone therapy use among menopausal women has fallen to just 1.8% as of 2023, data show, despite evidence and clinical guidance suggesting HT is safe and effective for most women for bothersome menopausal symptoms.

Patients with atrial fibrillation needing stroke prevention assigned to abelacimab had very low rates of bleeding during invasive procedures, according to new data from the AZALEA-TIMI 71 trial.

For older adults with non-STEMI, routine coronary intervention was safe but did not lower risk for death from CV causes or nonfatal MI compared with medical therapy alone, according to new data from the SENIOR-RITA trial.

Tirzepatide is associated with similar odds for gastrointestinal adverse events and a lower likelihood for diabetic retinopathy and pancreatitis compared with GLP-1 receptor agonists, according to a presenter.

In patients with heart failure and mildly reduced or preserved ejection fraction, finerenone improved outcomes compared with placebo regardless of baseline diabetes status, according to new data from the FINEARTS-HF trial.

Initiating dual antiplatelet therapy within 72 hours of symptom onset in patients with ischemic stroke or transient ischemic attack led to a significant reduction in new stroke occurrence at 90 days, according to results of a subgroup analysis.

In patients with atrial fibrillation and heart failure with reduced ejection fraction, cryoballoon ablation was noninferior to radiofrequency ablation, according to the results of the CRABL-HF trial.

Mass ECG screening for atrial fibrillation in older adults did not reduce the incidence of stroke or stroke hospitalization, according to the results of two trials presented at the European Society of Cardiology Congress.

Adults with type 2 diabetes at high risk for cardiovascular events were more likely to sustain an HbA1c of 6.5% or less at 2 years with tirzepatide if they lost more weight and had improved beta-cell function, according to new data.

Nearly one in 20 adults in the U.S. are estimated to have atrial fibrillation, many more than previous studies had indicated, according to new data out of the University of California, San Francisco.